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Abstract
Background—Preliminary data suggests a potential decreased benefit of docetaxel in metastatic
castration-resistant prostate cancer (mCRPC) patients previously treated with abiraterone acetate,
a novel androgen synthesis inhibitor (ASI). CALGB 90401 (Alliance), a phase 3 trial of mCRPC
patients treated with docetaxel-based chemotherapy, offered the opportunity to evaluate effect of
prior ketoconazole, an earlier generation ASI, on clinical outcomes following docetaxel.
Methods—CALGB 90401 randomized 1050 men with chemotherapy-naïve, mCRPC to
treatment with docetaxel and prednisone with either bevacizumab or placebo. 1005 men (96%)
had data available regarding prior ketoconazole therapy. The effect of prior ketoconazole on
overall survival (OS), progression-free survival (PFS), PSA decline, and objective response rate
(ORR) observed was assessed using proportional hazards and Poisson regression method adjusted
for validated prognostic factors and treatment arm.
Corresponding Author: Rahul Aggarwal, 1600 Divisadero, 3rd Floor, San Francisco, CA 94143, rahul.aggarwal@ucsf.edu, (P)
415.353.7171, (F) 415.353.7779.
The authors have no other financial disclosures, conflicts of interest, or acknowledgements.
NIH Public Access
Author Manuscript
Cancer. Author manuscript; available in PMC 2014 October 15.
Published in final edited form as:
Cancer. 2013 October 15; 119(20): 3636–3643. doi:10.1002/cncr.28285.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Results—Baseline characteristics between patients with (N=277) and without (N=728) prior
ketoconazole therapy were similar. There were no statistically significant differences between
patients with and without prior ketoconazole therapy with respect to OS (median OS 21.1 vs. 22.3
months, stratified log-rank p-value=0.635); PFS (median PFS 8.1 vs. 8.6 months, stratified log-
rank p-value=0.342); ≥50% PSA decline (61% vs. 66%, relative risk=1.09, adjusted p-
value=0.129); or ORR (39% vs. 43%, relative risk=1.11, adjusted p-value=0.366).
Conclusions—As measured by OS, PFS, PSA and ORR, there is no evidence that prior
treatment with ketoconazole impacts clinical outcomes in mCRPC patients treated with
subsequent docetaxel-based therapy. Prospective studies are needed to assess for potential cross-
resistance with novel ASIs and to define the optimal sequence of therapy in mCRPC.
Introduction
Prostate cancer is the second-leading cause of cancer-related mortality among men in the
United States [1]. Although a significant number of men with advanced disease eventually
succumb to metastatic castrate resistant prostate cancer (mCRPC), the past decade has borne
witness to multiple agents with varying mechanisms of action that have demonstrated an
improvement in overall survival in randomized phase 3, placebo-controlled, clinical trials.
Among these agents are taxane-based cytotoxic chemotherapy [2–4], androgen synthesis
inhibitors (ASIs) such as abiraterone acetate [5, 6], and the novel androgen receptor (AR)
antagonist enzalutamide (MDV3100) [7, 8]. Optimizing the sequence (or combinations) of
therapy, assessing for evidence of acquired cross-resistance, and discovering mechanisms of
treatment resistance have become of increasing clinical importance in the treatment of
mCRPC patients.
A retrospective, single institution series suggested that patients with mCRPC who are treated
with adrenal ASIs such as abiraterone acetate may acquire cross-resistance to subsequent
taxane-based chemotherapy [9]. The putative biological mechanism explaining this cross-
resistance stems from the observation that taxanes exert their anti-neoplastic effect in
prostate cancer in part by down-regulating signaling via the AR pathway. Taxanes exert this
effect by targeting AR association with tubulin, inhibiting AR nuclear translocation, and
down-regulating AR-mediated gene expression [10]. Thus, it is hypothesized that prior
exposure to agents targeting the androgen axis such as abiraterone acetate may shift the
tumor phenotype towards a more “androgen insensitive” disease state that is partially
resistant to further inhibition of androgen signaling with taxane-based chemotherapy.
Abiraterone acetate has only recently been FDA approved in mCRPC in both the pre- and
post-docetaxel setting. Ketoconazole is a generic, widely available androgen synthesis
inhibitor that has been in clinical use for mCRPC since the 1990s. Ketoconazole blocks
androgen synthesis via inhibition of several enzymes within the androgen synthetic pathway,
including side chain cleavase (which converts cholesterol to pregnenolone) and CYP 17
(which converts pregnenolone to the androgen dehydroepiandrostenedione (DHEA) via two
enzymatic steps, and is the same enzyme targeted by abiraterone) [11–14]. Ketoconazole has
demonstrated significant clinical activity in mCRPC in several prior prospective clinical
trials and is a standard treatment option in this disease setting [15, 16]. The Cancer and
Leukemia Group B, now a part of the Alliance for Clinical Trials in Oncology, designed
CALGB 90401, a randomized phase 3 trial in which 1050 mCRPC patients were treated
with docetaxel-based chemotherapy. This trial offered the opportunity to evaluate the effect
of prior treatment with ketoconazole, an earlier generation ASI, on clinical outcomes
following docetaxel treatment.
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Patients and Methods
Study Design and Hypothesis
A retrospective analysis of data collected from the intergroup study CALGB 90401, a
randomized, placebo-controlled phase 3 trial of docetaxel and prednisone with or without
bevacizumab in men with mCRPC [17] was undertaken. The objective was to assess
whether prior androgen synthesis inhibition with ketoconazole impacted clinical outcomes
with subsequent docetaxel-based chemotherapy, as a means to further investigate the
potential for acquired cross-resistance between these therapeutic approaches for men with
mCRPC.
Study Population
The eligibility requirements for CALGB 90401 have been previously described [17]. In
brief, eligible patients had metastatic prostate cancer with disease progression in the setting
of a castrate level of serum testosterone (≤ 50 ng/dL) and following anti-androgen
withdrawal, as defined by the Prostate-Specific Antigen Working Group1 consensus criteria
[18]. Patients were required to be ≥ 4 weeks from discontinuation of secondary hormonal
therapies including ketoconazole or antiandrogens. 5-Alpha reductase inhibitors were
required to be discontinued at any time prior to study entry. Prior bisphosphonate use was
allowed provided that the dose was stable for > 4 weeks prior to protocol therapy
(denosumab was not commercially available at the time). Key exclusion criteria included
prior chemotherapy or anti-angiogenic therapy, ECOG performance status > 2, uncontrolled
hypertension, congestive heart failure (New York Heart Association class II, III, or IV),
arterial thromboembolic event within 12 months of study entry, or grade ≥ 2 peripheral
neuropathy.
CALGB 90401 Study Design and Treatment
Patients enrolled onto CALGB 90401 were randomized with equal probability to receive
docetaxel/prednisone plus placebo or docetaxel/prednisone plus bevacizumab [17].
Randomization was stratified by: age (< 65 years, ≥ 65 years), predicted 24-month survival
probability using a validated CRPC nomogram [19] (< 10%, 10 to 29.9%, ≥ 30%), and prior
history of arterial thromboembolic events (yes, no). Treatment was continued until disease
progression or unacceptable toxicity for a maximum of 2 years. Patients were assessed by
serum PSA with each cycle of therapy and by bone scan + CT abdomen/pelvis every 3
months. The primary endpoint was overall survival, and as has been previously reported, no
difference between the arms was detected [17]. 1,050 patients were accrued between May
2005 and December 2007 across 310 investigational sites within the United States. CALGB
90401 was approved by the local ethics committees of all participating centers. Each
participant signed an IRB-approved, protocol-specific informed consent in accordance with
federal and institutional guidelines.
As part of the quality assurance program of the CALGB, members of the Audit Committee
visit all participating institutions at least once every three years to review source documents.
The auditors verify compliance with federal regulations and protocol requirements,
including those pertaining to eligibility, treatment, adverse events, tumor response, and
outcome in a sample of protocols at each institution. Such on-site review of medical records
was performed for a subgroup of 141 patients (13%) of the 1050 patients under this study.
Statistical Methods and Data Analysis
The primary endpoint was overall survival (OS), which was defined as the time interval
from date of randomization to date of death from any cause. In addition, the effect of prior
ketoconazole use on other endpoints such as progression-free survival (PFS), ≥ 50% decline
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in PSA from baseline, and objective response proportion as defined by RECIST 1.0 criteria)
was evaluated. PFS was defined from the date of randomization to date of progression or
death due to any cause, whichever occurred first. Progression was defined by using PSA
Working Group 1 criteria [18] with the exception that more than two new bone lesions were
required for bone progression on a bone scan.
Information about prior ketoconazole use was prospectively collected at the time of study
entry, prior to randomization, but data on duration of prior ketoconazole use, whether
ketoconazole was used in the hormone-sensitive or castration-resistant setting, or prior
response to ketoconazole were not prospectively collected on this trial. The Kaplan-Meier
product limit approach [20] was used to estimate the overall and progression-free survival
distribution as a function of prior ketoconazole use. The proportional hazards model [21]
was used to assess the prognostic significance of prior ketoconazole use in predicting OS
and PFS adjusting for the prospectively defined stratification factors and for the PFS
endpoint, the treatment arm (which has been previously reported to have an effect on PFS,
but not OS). The Poisson regression method [22] was used to assess the prognostic
significance of prior ketoconazole use in predicting the probability of at least 50% decline in
serum PSA from baseline and the probability of experiencing an objective response as
defined by RECIST 1.0 criteria adjusting for the stratification factors and treatment arm
[23]. Tests of treatment arm by prior ketoconazole use interaction in predicting outcomes on
docetaxel were performed and no significant interactions between were noted in predicting
clinical outcomes. Data collection and analysis was undertaken by the Alliance (formerly
CALGB) Statistical and Data Center. The date of data lock was January 13th, 2013.
S-plus statistical software (TIBCO Spotfire S+ version 8.1, TIBCO Spotfire Inc., Somerville,
MA) was used for the data analyses and all statistical tests were two-sided. No adjustment
was made for multiple comparisons for this retrospective analysis.
Results
Patient Disposition and Baseline Characteristics
1050 patients were randomized to receive docetaxel plus prednisone with or without
bevacizumab. Of these 1050 patients, 1005 (96%) had data available regarding prior
ketoconazole use (Figure 1). The baseline characteristics for these 1005 patients, including
known prognostic factors in mCRPC, are summarized in Table 1. Not surprisingly, the 4%
of patients for whom data was not available with regards to prior ketoconazole use had
similar demographic and baseline patient characteristics to the 96% of patients with
available data. Of the 1005 patients available for analysis, 28% had received prior treatment
with ketoconazole for CRPC. The two groups (those with and without prior ketoconazole)
had similar baseline characteristics including age, ECOG performance status, median
alkaline phosphatase and hemoglobin, and presence of visceral metastases. There were
numerical differences between groups in median baseline serum PSA and LDH, which were
higher in the group of patients with prior ketoconazole therapy. However, the two groups
had similar 24 month predicted survival probability using a validated prognostic model in
CRPC which incorporates PSA and LDH levels amongst its seven factors [19]. The median
baseline serum testosterone levels and study arm assignment between patients with and
without prior ketoconazole therapy were similar.
Impact of Prior Ketoconazole Therapy on Clinical Outcomes
A total of 968 deaths were observed and the median follow-up time for the alive patients
was 57 months (95% CI 52.3–59.7). The median overall survival times on CALGB 90401
was 21.1 months (95% CI 19.6–23.8) for patients with prior ketoconazole therapy and 22.3
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months (95% CI 21.1–24.0) for patients without prior ketoconazole use (p = 0.315). The
Kaplan-Meier overall survival curves are depicted in Figure 2A. Adjusting for the
stratification factors, the hazard ratio for death for patients who had prior ketoconazole use
was 1.04 compared with patients who did not use ketoconazole (95% CI 0.89–1.20, p =
0.635).
Similar results were obtained for progression-free survival; median PFS times for patients
with prior ketoconazole was 8.1 months (95% CI 7.6–9.4) versus 8.6 months (95% CI 8.0–
9.1) for patients without prior ketoconazole exposure (p = 0.177). Using a proportional
hazards model adjusting for treatment arm and the stratification factors, the hazard ratio for
PFS for patients who had prior ketoconazole use was 1.07 compared with patients without
ketoconazole use (95% CI 0.92–1.23, p = 0.342). The Kaplan-Meier PFS curves are shown
in Figure 2B.
Additional analyses were carried out examining the impact of prior ketoconazole therapy on
objective response rate (among patients with measurable disease at baseline) according to
RECIST 1.0 criteria as well as proportion of patients with ≥ 50% decline in PSA from
baseline on protocol docetaxel-based chemotherapy. There was no significant effect of prior
ketoconazole use on objective response rate or PSA declines ≥ 50% from baseline with
docetaxel-based therapy (Table 2).
Discussion
The current analysis suggests that prior exposure to the androgen synthesis inhibitor
ketoconazole does not impact clinical outcomes following docetaxel-based therapy in a large
cohort of patients with mCRPC, as measured by overall and progression-free survival,
objective response rate, and PSA decline ≥ 50%. The study results provide no evidence of
cross-resistance between androgen synthesis inhibition and taxane-based chemotherapy in
mCRPC. Though the use of ketoconazole in current clinical practice has significantly
declined with the introduction of agents like abiraterone and enzalutamide, the study results
may have implications for the sequencing of contemporary androgen synthesis inhibitors
prior to taxane-based chemotherapy in mCRPC, including abiraterone acetate and others in
clinical development (i.e. orteronel, galeterone). These newer agents share a similar
mechanism of action as ketoconazole with respect to inhibiting adrenal androgen
production, a key source of ligand for the androgen receptor in the castrate-resistant state
[24].
Two retrospective series of patients treated with abiraterone followed by docetaxel have
been recently reported [9, 25]. In one series of 35 patients treated with docetaxel following
disease progression on abiraterone, 25.7% (95% CI 12.5–43.3%) had a PSA decline ≥ 50%.
The median time to PSA progression and OS were 4.6 months (95% CI 4.2 – 5.9) and 12.5
months (95% CI 10.6 – 19.4), respectively, outcomes that are seemingly inferior to those
achieved in the registrational phase III trials of docetaxel in mCRPC [2, 3]. In contrast, in
another small retrospective case series of 14 patients treated with docetaxel following
disease progression on abiraterone, 43% of patients achieved ≥ 50% decline from baseline in
serum PSA, and the median time to progression on docetaxel (4.3 months) was qualitatively
similar to that achieved on prior abiraterone therapy (4.8 months) [25].
These retrospective analyses are intriguing. However, caution in their interpretation is
warranted, given the small sample sizes, the lack of comparator arms, and the potential for
selection bias as docetaxel therapy was chosen per individual treating physician discretion in
both series. In the current analysis, the large numbers of patients (1005 of the 1050 patients
enrolled onto CALGB 90401), the similar distribution in baseline prognostic factors among
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men with and without prior ketoconazole exposure, and the prospectively assessed outcomes
on docetaxel-based chemotherapy, provide support to the hypothesis that androgen synthesis
inhibition does not have a detrimental impact on subsequent taxane-based chemotherapy.
There are, however, a number of limitations to the present results. First, it is not known if
the potency of prior androgen synthesis inhibition may influence clinical outcomes with
subsequent taxane-based chemotherapy. Pre-clinical studies have demonstrated that
ketoconazole is a less potent androgen synthesis inhibitor compared to abiraterone acetate,
which selectively targets the CYP 17 enzyme [24]. In contrast to abiraterone, ketoconazole
has not demonstrated an overall survival benefit in the CRPC disease setting [16]. It is not
known if more potent androgen synthesis inhibition will result in the emergence of cross-
resistance to subsequent taxane-based chemotherapy.
Second, these results may have been confounded by a heterogeneous study population with
respect to duration of prior ketoconazole therapy, whether ketoconazole was applied in the
hormone-sensitive or castration-resistant setting, and reason for discontinuation of
ketoconazole, none of which were prospectively captured on CALGB 90401 and may
influence patterns of cross-resistance. It is possible that many patients received other
secondary hormonal agents prior to study enrollment, which may have influenced
subsequent clinical outcomes with ketoconazole and/or docetaxel-based chemotherapy.
Duration of and response to secondary hormonal maneuvers such as ketoconazole therapy
may provide a clinical measure of “androgen sensitivity” which could potentially influence
treatment outcomes with subsequent docetaxel therapy.
While the results of the current analysis suggest a lack of deleterious effect of prior
androgen synthesis inhibition on the efficacy of docetaxel-based chemotherapy, this does
not rule out the possibility of cross-resistance and ultimately highlights the need for future
studies addressing the sequencing of therapy in mCRPC. Prospective clinical trials designed
with adequate statistical power will be needed to test for potential cross-resistance between
various modalities of therapy and to define the optimal sequence of therapy in mCRPC.
Conclusions
As measured by OS, PFS, objective response rate, and decline in PSA ≥ 50%, there is no
evidence that prior treatment with the androgen synthesis inhibitor ketoconazole has an
impact on clinical outcomes in mCRPC patients with subsequent docetaxel therapy. Future
prospectively designed studies are needed to further assess for potential cross-resistance
between novel androgen synthesis inhibitors such as abiraterone acetate and taxane-based
chemotherapy and to define the optimal sequence of therapy as additional agents become
available for clinical use in mCRPC.
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Figure 1.
Patient disposition. 1050 patients were enrolled onto CALGB 90401.
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Figure 2.
(A) Kaplan-Meier curves for overall survival by prior ketoconazole exposure on CALGB
90401. OS = overall survival; keto = ketoconazole
(B) Kaplan-Meier curves for progression-free survival by prior ketoconazole exposure. PFS
= progression-free survival
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Table 1
Baseline Characteristics Among Men With and Without Prior Ketoconazole Use Enrolled Onto CALGB
90401
Variable
Prior Ketoconazole
N=277
No Prior Ketoconazole
N=728
Total
N=1005
Race
White 88% 88% 88%
Age
<65 34% 33% 33%
65+ years 66% 67% 67%
Median, years (inter-quartile range) 69.0 (62.0–75.0) 68.0 (62.0–74.0) 69.0 (62.0–75.0)
Prior history of arterial events
Yes 8% 8% 8%
No 92% 92% 92%
Predicted Survival Probability At 24-months*
 <10% 20% 17% 18%
 10%–29.9% 34% 34% 34%
 30%+ 45% 48% 47%
ECOG Performance Status
0 55% 55% 55%
1 42% 40% 41%
2 4% 5% 4%
Measurable Disease 52% 49% 50%
Sites of metastases
  Bone 88% 85% 86%
  Liver 4% 6% 6%
  Lung 10% 10% 10%
  Lymph node 45% 42% 43%
  Other 14% 14% 14%
Median (inter-quartile range)
 Alkaline Phosphatase U/L 122.0 (86.0–227.0) 117.0 (82.5–225.5) 119.0 (83.0–226.0)
 Hemoglobin g/dL 12.7 (11.5–13.8) 12.7 (11.7–13.8) 12.7 (11.7–13.8)
 LDH U/L 211.0 (170.0–332.0) 201.5 (164.0–282.5) 205.0 (166.0–298.0)
 PSA ng/mL 121.9 (47.2–316.6) 73.3 (25.6–228.7) 85.3 (31.0–241.6)
 Testosterone ng/dL 20.0 (10.0–26.0) 20.0 (11.0–27.0) 20.0 (11.0–27.0)
Treatment Arm
Docetaxel & Bevacizumab 52% 49% 50%
Docetaxel Only 48% 51% 50%
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*As assessed by a validated prognostic nomogram in CRPC [19].
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Table 2
Multivariable Analyses: Impact of Prior Ketoconazole Use on Clinical Endpoints in CALGB 90401.
Prior Ketoconazole Use
Clinical Endpoint Yes (n=277) No (n=728) HR (95% CI) p-value
Median OS (months) (95% CI) 21.1 (19.7–24.2) 22.3 (21.2–24.0) 1.04 (0.90–1.20) 0.635*
Median PFS (months) (95% CI) 8.1 (7.6–9.4) 8.6 (8.0–9.1) 1.07 (0.93–1.24) 0.342**
≥50% decline in PSA (95% CI) 61% (54–67) 66% (63–70) 1.09 (0.98–1.21)*** 0.129**
Objective Response (95% CI) (Patients with measurable
disease) 39% (31–47) (156) 43% (38–49) (356) 1.11 (0.88–1.41)*** 0.366**
*Adjusted for the stratification factors (age, prior history of AE and predicted overall survival probability at 24-months).
**Adjusted for the stratification factors (age, prior history of AE and predicted overall survival probability at 24-months) and treatment arm.
***
Relative risk estimate using a modified Poisson regression approach [22].
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